Please note: The information displayed on this page might be outdated.
Targovax: Oncolytic adenovirus armed w immune stimulating transgene targeting basket of I-O indications. Strong results from Part 1 (ONCOS-102/Keytruda combo) trial in anti-PD1 refractory melanoma: 33% ORR in 9 pts: 1 CR, 2 PRs; immune act. in all 9 pts. Upcoming milestones: randomized data, Ph 1b/2 (mesothelioma, n=31) w/chemo: Jan 2020; Ph 1, Part 2 data (melanoma comb w/Keytruda, n=21): 1H2020; updates from collab partners in peritoneal metastasis & prostate exp 2020
Based in...
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Oncology
Public, USA
Market Cap
Therapeutic Modalities
Platform Technology, Vaccine
Vollsveien 19
Lysaker, Oslo NO-1366

Company Participants at Solebury Trout KOL Day

  • Torbjørn Furuseth, Chief Financial Officer

Upcoming Company Event Participation

Top 10 Holders of Targovax ASA

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Nordea Investment Management AB (Norway) 5.63 4,278,925 0.00 Stakes 10/26/20
Fjärde AP-fonden 5.26 4,000,000 0.00 Stakes 10/26/20
Arctic Fund Management AS (Sweden) 1.70 1,290,959 0.00 Funds 12/31/20
MP Pensjon PK 1.59 1,207,770 0.00 Stakes 10/26/20
Forte Fondsforvaltning AS 0.66 500,000 0.00 Funds 1/29/21
Storebrand Asset Management AS 0.39 295,000 0.00 Funds 1/31/21
Handelsbanken Fonder AB 0.23 172,431 0.00 Funds 1/31/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.